At the humoral level, the infarct-reducing effect of CH may be mediated by catecholamines, cholinergic and endogenous opioids, ANP, erythropoietin, endothelin-1, adrenomedullin, and related membrane receptors. This evidence concerns the gene EPO and cyclic hematopoiesis.